

Natco Pharma releases Hepatitis C drug in India

03 July 2018 | News

The product is a generic fixed dose combination of Sofosbuvir 400 mg and Daclatasvir 60mg tablets.



Fixed dose combination of Sofosbuvir-Daclatasvir tablets for the treatment of Hepatitis C under the brand name Hepcinat Plus, has been launched by Natco Pharma in India.

The product is a generic fixed dose combination of Sofosbuvir 400 mg and Daclatasvir 60mg tablets, used for the treatment of patients with chronic Hepatitis C virus (HCV) infection

The company has launched the drug at a maximum retail price of Rs 17,500 for a bottle of 28 tablets.